Maraviroc
Maraviroc (sold under the brand name Selzentry or Celsentri) is an antiretroviral medication approved by the FDA for treatment of HIV. It is one of the antivirals that is recommended by the Front Line COVID-19 Critical Care Alliance (FLCCC)[1] and Bruce Patterson's IncellDx for the treatment of Long COVID.[2][3] It may also be of use in treating ME/CFS.
Theory[edit | edit source]
Maraviroc prevents the virus from attaching to the cell after replication, as well as the penetration of the virus into the cell. Maraviroc does not affect replication, does not promote virus mutation, and prevents the reproduced virus from gaining a foothold in the cell. Thus, treatment is carried out by displacing the virus from tissues, and not by preventing replication
Evidence[edit | edit source]
The study, which ended in the United States in Nevada, Nebraska on November 12, 2023, has cumulative results 526 out of 774 people were cured in 190 days of taking the drug
ME/CFS[edit | edit source]
Clinicians[edit | edit source]
Risks and safety[edit | edit source]
Cost and availability[edit | edit source]
Maraviroc is approved for use in the United States by the FDA, and and is approved for medical use in the European Union. In 2022 a generic version was approved by the FDA and placed into production. Pharmacy costs for generic Maraviroc range from $200 - $1,400 USD for a one month supply (60 tablets.)
Notable studies[edit | edit source]
- 2022, Targeting the monocytic-endothelialplatelet axis with maraviroc and pravastatin as a therapeutic option to treat long COVID/Post-acute sequelae - Targeting the Monocytic-Endothelial-Platelet Axis with Maraviroc and Pravastatin as a Therapeutic Option to Treat Long COVID/ Post-Acute Sequelae of COVID (PASC)[4] - (Full text, preprint)
Learn more[edit | edit source]
See also[edit | edit source]
References[edit | edit source]
- ↑ Marik, Paul (2022). "An overview of the MATH+, I-MASK+ and I-RECOVER Protocols. A Guide to the Management of COVID-19" (PDF). Front Line COVID-19 Critical Care Alliance. p. 22. Retrieved March 29, 2023.
- ↑ "IncellDx Awarded Patent for Use of CCR5 Antagonist Maraviroc in Treatment of COVID-19". Business Wire. November 23, 2021. Retrieved March 29, 2023.
- ↑ Shaffer, Leah (September 6, 2022). "Lots of long COVID treatment leads, but few are proven". Proceedings of the National Academy of Sciences. 119 (36): e2213524119. doi:10.1073/pnas.2213524119. ISSN 0027-8424. PMC 9456722. PMID 36048910.
- ↑ Patterson, Bruce; Yogendra, Ram; Guevara-Coto, Jose; Mora-Rodriguez, Rodrigo; Osgood, Eric; Bream, John; Parikh, Purvi; Kreimer, Mark; Kaplan, Gary; Zgoda, Michael (February 10, 2022). "Targeting the Monocytic-Endothelial-Platelet Axis with Maraviroc and Pravastatin as a Therapeutic Option to Treat Long COVID/ Post-Acute Sequelae of COVID (PASC)". ResearchSquare. doi:10.21203/rs.3.rs-1344323/v1.
